biostudies-literatureYerushalmy-Feler ANIDDK NIH HHSjjae182https://www.ebi.ac.uk/biostudies/studies/S-EPMC12548835biostudies-literatureUnknown19(5)<h4>Background and aims</h4>Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U.<h4>Methods</h4>In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction.<h4>Results</h4>One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologicJournal of Crohn's & colitisUpadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.PMC12548835K23 DK119585Urlep DAncona SUhlig HHYerushalmy-Feler AGranot MWlazlo MYogev DHradsky OHojsak ITurner DRinawi FRungo CMitrova KKang BShouval DSOlbjorn CHackl LSansotta NTzivinikos CMagen Rimon RSuskind DLTrindade ESpencer EAConrad MANorsa LPujol-Muncunill GCohen SKolho KLScarallo LVelasco Rodriguez-Belvis MBramuzzo MGasparetto MD'Arcangelo GDolinger MTKelsen JRfalseUpadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.<h4>Background and aims</h4>Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U.<h4>Methods</h4>In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction.<h4>Results</h4>One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologic2025-01-01T00:00:00Z2025 May2026-06-04T16:38:14.856Z2026-05-13T14:24:39.086ZS-EPMC125488353960528610.1093/ecco-jcc/jjae182